Group One Trading’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.2M Buy
317,800
+42,800
+16% +$1.84M 0.02% 709
2026
Q1
$10.1M Sell
275,000
-248,200
-47% -$11.8M 0.02% 836
2025
Q4
$26.6M Sell
523,200
-403,200
-44% -$20.6M 0.05% 397
2025
Q3
$51.4M Sell
926,400
-79,000
-8% -$4.62M 0.09% 203
2025
Q2
$69.4M Buy
1,005,400
+528,300
+111% +$35.9M 0.15% 104
2025
Q1
$33.1M Buy
477,100
+192,900
+68% +$15.9M 0.1% 171
2024
Q4
$24.4M Buy
284,200
+231,800
+442% +$25.1M 0.06% 305
2024
Q3
$6.24M Buy
52,400
+5,300
+11% +$707K 0.02% 878
2024
Q2
$6.72M Sell
47,100
-8,300
-15% -$1.1M 0.03% 636
2024
Q1
$7.11M Sell
55,400
-36,200
-40% -$4.31M 0.03% 604
2023
Q4
$9.48M Buy
91,600
+1,400
+2% +$138K 0.02% 728
2023
Q3
$8.2M Buy
90,200
+54,800
+155% +$4.83M 0.03% 629
2023
Q2
$2.86M Buy
35,400
+10,600
+43% +$866K 0.01% 1397
2023
Q1
$1.97M Buy
24,800
+17,000
+218% +$1.21M 0.01% 1538
2022
Q4
$528K Buy
7,800
+4,000
+105% +$235K ﹤0.01% 2997
2022
Q3
$189K Buy
3,800
+2,200
+138% +$118K ﹤0.01% 4200
2022
Q2
$89K Hold
1,600
﹤0.01% 5091
2022
Q1
$89K Sell
1,600
-64,800
-98% -$3.33M ﹤0.01% 5608
2021
Q4
$3.72M Buy
66,400
+63,400
+2,113% +$3.43M ﹤0.01% 1971
2021
Q3
$144K Sell
3,000
-8,200
-73% -$396K ﹤0.01% 5517
2021
Q2
$469K Buy
11,200
+7,800
+229% +$302K ﹤0.01% 4288
2021
Q1
$115K Sell
3,400
-9,400
-73% -$335K ﹤0.01% 5533
2020
Q4
$447K Buy
12,800
+9,600
+300% +$332K ﹤0.01% 3360
2020
Q3
$111K Sell
3,200
-2,000
-38% -$66.7K ﹤0.01% 4120
2020
Q2
$170K Buy
5,200
+400
+8% +$12.8K ﹤0.01% 3521
2020
Q1
$144K Sell
4,800
-2,600
-35% -$77.4K ﹤0.01% 3006
2019
Q4
$214K Sell
7,400
-69,000
-90% -$1.91M ﹤0.01% 3121
2019
Q3
$1.98M Buy
76,400
+76,200
+38,100% +$1.93M 0.02% 1231
2019
Q2
$5K Sell
200
-1,000
-83% -$24.7K ﹤0.01% 4607
2019
Q1
$31K Buy
+1,200
New +$29.5K ﹤0.01% 3828
2018
Q4
Sell
-200
Closed -$5K 5237
2018
Q3
$5K Buy
+200
New +$4.88K ﹤0.01% 4847
2018
Q2
Sell
-2,000
Closed -$49K 5349
2018
Q1
$49K Buy
2,000
+1,400
+233% +$36.8K ﹤0.01% 3666
2017
Q4
$16K Buy
+600
New +$15.3K ﹤0.01% 4226
2017
Q3
Sell
-6,200
Closed -$133K 5050
2017
Q2
$133K Buy
6,200
+2,600
+72% +$52.5K ﹤0.01% 2935
2017
Q1
$62K Buy
3,600
+800
+29% +$13.9K ﹤0.01% 3276
2016
Q4
$50K Sell
2,800
-66,800
-96% -$1.21M ﹤0.01% 3264
2016
Q3
$1.45M Buy
+69,600
New +$1.73M 0.02% 1027
2016
Q2
Sell
-12,600
Closed -$341K 4840
2016
Q1
$341K Buy
12,600
+11,200
+800% +$300K ﹤0.01% 1970
2015
Q4
$41K Buy
+1,400
New +$38.8K ﹤0.01% 3525
2015
Q3
Sell
-6,800
Closed -$186K 5082
2015
Q2
$186K Sell
6,800
-13,400
-66% -$377K ﹤0.01% 2573
2015
Q1
$539K Buy
20,200
+5,400
+36% +$124K 0.01% 1530
2014
Q4
$313K Buy
14,800
+14,600
+7,300% +$326K ﹤0.01% 1931
2014
Q3
$5K Sell
200
-17,800
-99% -$410K ﹤0.01% 4723
2014
Q2
$416K Sell
18,000
-17,400
-49% -$384K 0.01% 1794
2014
Q1
$808K Sell
35,400
-19,600
-36% -$418K 0.01% 1249
2013
Q4
$1.02M Sell
55,000
-143,000
-72% -$2.49M 0.02% 1088
2013
Q3
$3.35M Buy
198,000
+123,000
+164% +$2.07M 0.06% 329
2013
Q2
$1.16M Buy
+75,000
New +$1.25M 0.03% 714

Other funds holding NVO

Group One Trading's NVO Position: Q2 2026 in Review

Group One Trading reduced its Novo Nordisk (NVO) stake by 40% in Q2 2026, selling an estimated $1.78M and leaving 63,042 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

Group One Trading first reported a position in NVO in Q2 2013 and has held it in 34 quarters since. The position peaked at $21.2M in Q1 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Group One Trading held 63,042 shares of Novo Nordisk worth $3.02M as of Q2 2026.
  • Group One Trading sold 41,409 Novo Nordisk shares in Q2 2026, an estimated $1.78M.
  • Novo Nordisk made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #1833 holding.
  • Group One Trading first reported a position in Novo Nordisk in Q2 2013 and has held it in 34 quarters since.
  • Group One Trading's Novo Nordisk position peaked at $21.2M in Q1 2025.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.